News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

Heat Stroke and Heat-Related Illness Rapidly Rising as Global Temperatures Climb

Centre for Neuro Skills

The number of people exposed to extreme heat has grown exponentially due to climate change, according to the World Health Organization. The New York Times reported that June 2024 was the 13 th consecutive month to break the global heat record. In 2023, 32 million people across California, Texas and Nevada experienced the hottest summer ever recorded in the United States. Centre for Neuro Skills (CNS), a leading provider of traumatic and acquired brain injury rehabilitation services with seven locations in California and Texas, shares essential tips for heat stroke prevention. Taking proactive measures to avoid heat stroke can be the difference between life and death. To avoid heat stroke: Dress in lightweight, loose-fitting clothing Apply sunscreen to avoid sunburn and keep the body cool Drink plenty of water and avoid sugary or alcoholic drinks Limit time outside to when it is cooler or if you must go out when temperatures are high, rest often Avoid leaving children or animals in parked cars, even if the windows are cracked open Monitor loved ones who are at high risk for developing heat stroke Check local news for extreme heat alerts “Of all the heat-related illnesses, heat stroke is the most serious. Heat stroke occurs when the body is no longer able to regulate temperature and cool down,” said Dr. Gary Seale, Regional Director of Clinical Services at CNS. “Body temperatures can rise rapidly to 104 degrees or higher which can cause damage to organs, including the brain, and result in permanent disability. Heat stroke can cause brain swelling, seizures, and lead to chronic inflammation, all of which disrupt brain function.” Children under 4 years old, adults over 65 years old with illnesses or medications that prevent body temperature regulation and people that are clinically classified as obese are all at higher risk of heat stroke. Heat exhaustion can be caused by engaging in strenuous activity, overexposure to hot weather and humidity and wearing excessive clothing that does not allow sweat to evaporate. Symptoms of heat stroke include high body core temperature, flushed skin, dizziness, loss of consciousness for longer than a few seconds, rapid heart rate, difficulty breathing, muscle cramps, seizures, vomiting and diarrhea. If you or a loved one are showing signs of heat stroke, call 911 immediately or transport the person to the hospital. While waiting for help, keep the person in a cool environment, remove unnecessary clothing and apply ice packs or cool water to their skin. ### About Centre for Neuro Skills Centre for Neuro Skills (CNS) is an experienced and respected world leader that provides intensive rehabilitation and medical programs for those recovering from all types of brain injury. CNS covers a full spectrum of advanced acquired and traumatic brain injury rehabilitation care, from residential and assisted living programs to outpatient rehabilitation, day treatment and telehealth services. Founded by Dr. Mark Ashley in 1980, CNS has seven locations in California and Texas and has been recognized by the American Stroke Association for its work in stroke rehabilitation. For more information about Centre for Neuro Skills, visit: www.neuroskills.com, Instagram, Facebook, X (formerly known as Twitter), LinkedIn, and YouTube. Media, please note: To request an interview with CNS leadership or clinical staff, please contact Robin Carr at 415.766.0927 or CNS@landispr.com. Contact Details Landis Communications Inc. Robin Carr +1 415-766-0927 cns@landispr.com Company Website https://www.neuroskills.com/

July 23, 2024 08:01 AM Pacific Daylight Time

Article thumbnail News Release

Classiq Transforms Quantum Computing with Qmod, The First High-Level Language for Quantum Programming

Classiq Technologies

Classiq today announced the general availability of Qmod (Quantum Modeling Language), the first high-level language (HLL) for quantum coding. Following successful pilot projects with enterprise partners, Qmod is now accessible to developers, researchers and enterprises worldwide and will transform quantum computing with its efficient, approachable method of programming. Qmod facilitates advanced quantum modeling and enables developers to describe quantum algorithms at a high level of abstraction. It supports unique quantum-computing concepts alongside conventional constructs found in high-level classical programming languages. This innovative approach allows developers to focus on the functional intent of their algorithms while Classiq’s powerful compiler and synthesis engine handle the intricate hardware-aware quantum implementation details. “To deliver a business or scientific value, quantum computing must be useful and accessible to scientists and engineers seeking to use quantum computing to solve real-world problems, which today it is not,” said Heather West, PhD, Research Manager, Quantum Computing at IDC. “Today, programming a quantum computer happens at the hardware level, making the technology only accessible to quantum physicists and other quantum specialists. As we begin to talk about quantum utility and near-term applications, abstraction-level application programming will become a necessity for wide-spread quantum adoption and usage.” Why The Qmod Language Is Different Declarative programming: Qmod’s declarative nature lets users define what their algorithm should achieve rather than how to achieve it; Classiq’s synthesis engine compiler optimizes for hardware and other constraints automatically. Flexibility and interoperability: Whether through native syntax, Python or graphical representation, Qmod descriptions are easily translatable and compatible across different formats and hardware. Industry-ready: Qmod is a tool for researchers and industry applications, providing robust scalable solutions for enterprise-grade quantum software development in an era of steadily growing qubit counts and the resulting coding complexity. “As we go further in building a complete quantum software stack, our groundbreaking Qmod language enables quantum experts to produce sophisticated programs while also allowing developers without a quantum background to innovate and solve complex problems across a variety of industry domains,” said Nir Minerbi, CEO and co-founder of Classiq. “By abstracting the complexities of quantum programming, Qmod delivers the ability to create and deploy dynamic quantum applications effortlessly. In some cases, it’ll use perhaps five lines of code instead of the traditional 100 lines of code. Like Java for the worldwide web or BASIC for PCs, Qmod is intended to open the gates to advanced quantum implementation.” Classiq’s platform ensures that quantum algorithms designed with Qmod can be seamlessly compiled for a broad range of hardware and simulation environments, as well as supporting seamless HPC integration. The platform's synthesis engine dynamically adapts implementations to different hardware configurations, allowing for rapid benchmarking and ensuring optimal implementations that make the very most of the available hardware. About Classiq Classiq Technologies, the leading quantum software company, provides an all-encompassing platform (IDE, compiler and OS) with a single point of entry into quantum computing, taking you from algorithm design to execution. The high-level descriptive quantum software development environment, tailored to all levels of developer proficiency, automates quantum programming. This ensures that a broad range of talents, including those with backgrounds in AI, ML and linear algebra, can harness quantum computing without requiring deep, specialized knowledge of quantum physics. Classiq democratizes access to quantum computing and equips its users to take full advantage of the quantum computing revolution, including access to a broad range of quantum hardware. Classiq’s core technology, algorithmic quantum circuit compilation, is engineered to power the quantum ecosystem of today and the future. Classiq works closely with quantum cloud providers and advanced computation hardware developers providing software for use with quantum computers, HPC, and quantum simulators. Backed by investors such as HPE, HSBC, Samsung, Intesa Sanpaolo and NTT, Classiq’s world-class team of scientists and engineers has distilled decades of quantum expertise into its groundbreaking quantum engine. Follow Classiq on LinkedIn, X (formerly Twitter) or YouTube, and visit the Slack community and https://www.classiq.io to learn more. Contact Details Rainier Communications Michelle Allard McMahon classiqPR@rainierco.com Company Website http://www.classiq.io/

July 23, 2024 08:00 AM Eastern Daylight Time

Image
Article thumbnail News Release

Classiq and QuEra Announce Integration of Neutral-Atom Quantum Computers into Classiq Platform

Classiq Technologies

Classiq, the leader in quantum software development, and QuEra Computing, the leader in neutral-atom quantum computing, today announced a strategic collaboration to integrate QuEra’s cutting-edge neutral-atom quantum computers into the Classiq platform. This integration will enable customers to optimize a wide variety of quantum and hybrid quantum/classical algorithms for QuEra’s quantum computers, leveraging the unique capabilities of QuEra’s advanced quantum technology. With this collaboration, Classiq users will be able to exploit the distinctive features of QuEra’s neutral-atom quantum computers, such as the ability to simultaneously operate on multiple qubits and advanced qubit shuttling. Additionally, the integration provides access to Classiq’s extensive pre-written algorithmic blocks and allows customers to estimate the resources needed to run their algorithms. These capabilities enable the creation of highly resource-efficient algorithms with a large number of qubits and, in the future, for logical qubits as well. “Our partnership with QuEra represents a significant step forward in the quantum computing landscape,” said Nir Minerbi, CEO of Classiq. “By integrating QuEra’s neutral-atom technology into our platform, we are providing our users with unprecedented opportunities to enhance and optimize their quantum algorithms. This collaboration underscores our commitment to delivering the most versatile and powerful quantum computing solutions available.” “We are thrilled to collaborate with Classiq and bring the power of our neutral-atom quantum computers to a broader audience,” said Yuval Boger, Chief Commercial Officer of QuEra. “Classiq’s platform is renowned for its ease of use and flexibility, and by integrating our technology, we can help users unlock new potential and achieve groundbreaking results in their quantum computing projects.” The integration of QuEra’s quantum computers into the Classiq platform is expected to accelerate the development and deployment of quantum applications across various fields, including pharmaceuticals, finance, logistics and more. Customers who have purchased on-premises computers will be able to use the Classiq platform for the rapid development of quantum algorithms. This partnership highlights the ongoing commitment of both companies to drive innovation and make quantum computing more accessible and impactful. About Classiq Classiq Technologies, the leading quantum software company, provides an all-encompassing platform (IDE, compiler and OS) with a single point of entry into quantum computing, taking you from algorithm design to execution. The high-level descriptive quantum software development environment, tailored to all levels of developer proficiency, automates quantum programming. This ensures that a broad range of talents, including those with backgrounds in AI, ML and linear algebra, can harness quantum computing without requiring deep, specialized knowledge of quantum physics. Classiq democratizes access to quantum computing and equips its users to take full advantage of the quantum computing revolution, including access to a broad range of quantum hardware. Classiq’s core technology, algorithmic quantum circuit compilation, is engineered to power the quantum ecosystem of today and the future. Classiq works closely with quantum cloud providers and advanced computation hardware developers providing software for use with quantum computers, HPC, and quantum simulators. Backed by investors such as HPE, HSBC, Samsung, Intesa Sanpaolo and NTT, Classiq’s world-class team of scientists and engineers has distilled decades of quantum expertise into its groundbreaking quantum engine. Follow Classiq on LinkedIn, X (formerly Twitter) or YouTube, and visit the Slack community and https://www.classiq.io to learn more. About QuEra QuEra Computing is the leader in commercializing quantum computers using neutral atoms—widely recognized as a highly promising quantum modality. Based in Boston and built on pioneering research from nearby Harvard University and MIT, QuEra operates the world’s largest publicly accessible quantum computer, available over a major public cloud and for on-premises delivery. QuEra is developing large-scale, fault-tolerant quantum computers to tackle classically intractable problems, becoming the partner of choice in the quantum field. Simply put, QuEra is the best way to quantum. For more information, visit us at quera.com and follow us on X or LinkedIn. Contact Details Rainier Communications on behalf of Classiq Michelle Allard McMahon classiqPR@rainierco.com Merrill Freund on behalf of QuEra +1 415-577-8637 press@quera.com Company Website http://www.classiq.io/

July 23, 2024 08:00 AM Eastern Daylight Time

Article thumbnail News Release

Top 4 Cannabis Stocks to Watch Ahead of Potential Federal Policy Changes

RazorPitch KDLY, TLRY, CGC, ACB

When it comes to investing in the legal marijuana industry, they don't call it the "green rush" for nothing. Many analysts are projecting massive growth for the cannabis industry. New Frontier, a Washington D.C.-based cannabis research firm, expects total U.S. legal cannabis sales to exceed $57 billion by 2030. In light of such tremendous growth potential, many see marijuana as a golden investment opportunity. Cannabis is now legal in 37 states for medical use and fully legal in 23 states. However, on a federal level, its status has barely changed since the 1970s, sharing the same classification as heroin, ecstasy, and LSD. Cannabis stocks jumped after the U.S. Department of Health and Human Services recommended easing restrictions on marijuana in August. With that date approaching, let's take a look at a few stocks in the sector for your radar. KindlyMD, Inc. (NASDAQ: KDLY) is a healthcare company focused on integrating traditional primary care and pain management with behavioral and alternative therapies to combat opioid dependency in the U.S. As Utah's largest alternative pain treatment center, KindlyMD prioritizes holistic pain management and often recommends medical cannabis to improve patient health outcomes. In response to the ongoing opioid crisis, which saw over 80,000 opioid-related deaths in 2021, KindlyMD offers comprehensive care plans to ensure the safe use of opioids when necessary, including appropriate dosing and weaning plans. The company also educates patients on medical cannabis as an alternative treatment option, having conducted over 60,000 patient visits to date. Last month, KindlyMD successfully completed its initial public offering, raising approximately $6.8 million. This milestone demonstrates strong investor confidence in the company's comprehensive approach to healthcare. KDLY announced in June that it had become the first alternative medical treatment company in Utah to sign contracts with the state's top insurance payors, including Select Health, Medicare, and Medicaid. This credentialing allows nearly 70% of Utah's population to access KindlyMD's services through their insurance plans. Tim Pickett, PA-C, founder and CEO, stated, "This is a major milestone for KindlyMD. Now, the scope of services we provide at our Company-branded clinics, including behavioral healthcare and medical interventions incorporating alternative medicine, are covered by and reimbursable by the largest insurance providers across the state." On June 10, KDLY announced a collaboration with Curaleaf Holdings, Inc., (OTCQX: CURLF) to expand patient education on medical cannabis in Utah. This partnership includes community care events throughout the summer, aiming to enhance patient understanding of holistic pain management. Pickett noted, "Our collaboration with Curaleaf will provide more patients with access to pain management treatment options and alternative therapies, including medical cannabis care in the state of Utah." Additionally, KindlyMD further strengthened its position by contracting with Blue Cross Blue Shield, increasing its statewide insurance coverage to nearly 80%. Pickett commented, "The addition of Blue Cross Blue Shield under Utah's leading insurance payors reflects our commitment to transforming healthcare and making a meaningful difference in people's lives." As the cannabis industry continues to gain momentum, KDLY stands out for its unique approach to integrating medical cannabis into comprehensive pain management and behavioral health plans. This strong foundation, coupled with the company’s expanding insurance coverage and successful partnerships, positions KindlyMD for potential growth. For investors looking to tap into the burgeoning cannabis market, KDLY presents a compelling opportunity. Tilray Brands, Inc. (NASDAQ: TLRY) is a global leader in medical cannabis, dedicated to improving patient lives through a diverse portfolio of brands including Tilray, Aphria, Broken Coast, Symbios, and Navcora. From its origins as a licensed producer in Canada, Tilray has expanded its operations to Europe, establishing GMP-certified production facilities in Portugal and Germany. Today, Tilray Medical is a major supplier of medical cannabis across 20 countries and five continents, serving patients, healthcare professionals, and governments. Recently, Tilray announced it will release its financial results for the fourth quarter and full fiscal year ended May 31, 2024, on July 29, 2024, at market close. Despite recent fluctuations in share price, Tilray remains a formidable player in the cannabis industry, demonstrating long-term strength through its expanding craft beer business. Acquiring brands from Anheuser-Busch in 2023, Tilray has doubled its alcohol sales, diversifying its revenue streams and enhancing its position in a competitive market. TLRY’s strategic investments include building a $250 million cash reserve to support future acquisitions and operational expansion. This move, while diluting shares, positions Tilray advantageously for growth in the evolving cannabis sector. The company holds the top market share in Canada and Germany and distributes medical cannabis globally. In its Q3 2024 report, TLRY reported revenue of $188.3 million, a 30% increase from the previous year, although it fell short of the $198.3 million analysts' expectations. The company significantly reduced its loss to $82.1 million from $1.2 billion a year ago. With notable hedge fund interest and a robust portfolio, TLRY is well-positioned to benefit from potential federal legalization of medical cannabis in the U.S. Irwin Simon, CEO, highlighted Tilray's readiness to capitalize on regulatory changes, particularly the potential rescheduling of cannabis to Schedule III, which would facilitate the sale of pharmaceutical-grade products in the U.S. Canopy Growth Corporation (NASDAQ: CGC) is a global leader in the cannabis industry, committed to enhancing lives through innovative products and a diverse brand portfolio. With notable brands like Doja, 7ACRES, Tweed, and Deep Space, as well as vaporizer technology from Storz & Bickel, Canopy Growth stands out for its dedication to premium and mainstream cannabis products. The company recently reported its financial results for the fourth quarter and fiscal year ended March 31, 2024. For Q4 FY2024, Canopy Growth achieved a 7% increase in net revenue year-over-year, or 16% excluding divested businesses. This growth was significantly driven by a 43% revenue increase from Storz & Bickel, reflecting strong sales of the new Venty portable vaporizer. The Canadian cannabis sector saw a 16% rise in medical cannabis revenue, contributing to a 4% increase in overall Canadian cannabis revenue. In fiscal year 2024, Canopy Growth made impressive strides in reducing costs. The total cost of goods sold (COGS) decreased by 45%, with Canadian cannabis COGS dropping 54% year-over-year. Consolidated gross margins improved to 27%, marking a significant 4,600 basis point increase from the previous year. Despite an operating loss of $229 million and an adjusted EBITDA loss of $59 million, Canopy Growth showed a 72% improvement in adjusted EBITDA loss compared to FY2023. The company's financial stability is also notable, with $203 million in cash, cash equivalents, and short-term investments as of March 31, 2024. Strengthening balance sheet actions have positioned Canopy with no material debt obligations until March 2026. David Klein, CEO of Canopy Growth, highlighted the company’s strong foundation for future growth, emphasizing its momentum in the global cannabis markets and its readiness to capitalize on regulatory advancements in Germany and the U.S. As Canopy Growth enters FY2025, its broad portfolio of impactful brands and expanding U.S. ecosystem set the stage for continued success. Aurora Cannabis Inc. (NASDAQ: ACB), headquartered in Edmonton, Alberta, is a leading global player in the cannabis industry, serving medical and recreational markets across Canada, Europe, Australia, and South America. The company has built a diverse portfolio of cannabis brands, including Aurora Drift, San Rafael '71, Daily Special, Tasty's, and Greybeard for adult use, and MedReleaf, CanniMed, Aurora, and Whistler Medical Marijuana Co. for medical purposes. Additionally, Aurora's international brands include Pedanios, Bidiol, IndiMed, and CraftPlant. Aurora's strategic focus on innovation and high-quality products has positioned it as a significant force in the global cannabis market. The company recently reported its financial results for the fiscal year 2024, highlighting substantial improvements and operational efficiency. For Q4 2024, Aurora Cannabis achieved a 5% year-over-year increase in total net revenue, reaching $67.4 million. The global medical cannabis sector drove this growth, with net revenue rising 20% to $45.6 million. The company's strong performance in medical cannabis was bolstered by the acquisition of MedReleaf Australia and increased sales in Poland and the UK. Aurora's record annual adjusted EBITDA of $12.8 million marks its sixth consecutive quarter of positive adjusted EBITDA, reflecting the company's effective cost management and revenue growth. Aurora ended the fiscal year with approximately $180 million in cash and is debt-free in its cannabis business. The company remains focused on achieving positive free cash flow by the end of 2024. According to CEO Miguel Martin, Aurora's leadership in the global medical cannabis market is distinguished by its ability to meet diverse patient needs worldwide, underscored by a significant increase in its quarterly adjusted gross margin to 66%. With a solid financial foundation and a robust global presence, Aurora Cannabis is well-positioned for continued growth and success in the evolving cannabis industry. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by Cambridge Consulting to assist in the production and distribution of content related to KDLY. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details Mark McKelvie +1 585-301-7700 Company Website http://razorpitch.com

July 22, 2024 07:00 AM Eastern Daylight Time

Article thumbnail News Release

BestGrowthStocks.Com Issues Analysis on the Next Beneficiaries of the AI Revolution

SoundHound AI Inc.

NEW YORK, NY / NewsDirect / July 22nd, 2024 / Best Growth Stocks, a leading independent equity research and corporate access firm focused on finding and reporting on the best growth stocks utilizing exclusive ai-assisted research recently issued a comprehensive analysis of SoundHound AI, Inc. a pioneer in advanced voice-enabled AI and conversational intelligence technologies and a comprehensive analysis of the next beneficiaries of the AI revolution. SoundHound AI, Inc. (NASDAQ: SOUN) has garnered significant investor attention following multiple recent announcements that could prove to be significant catalysts for the AI company. Best Growth Stock's full report offers an analysis of SoundHound’s operations, potential upcoming catalysts, growth drivers, financials, share structure, chart, and more. Bonus content “The Next Beneficiaries of the AI Revolution” offers a comprehensive analysis of the next beneficiaries of the AI revolution, which ones stand to benefit near term, and stocks under $15/share to watch within each sector. Access this full analysis and bonus AI report with no obligation: https://bestgrowthstocks.com/soun-analysis/ Access this full analysis and bonus AI report with no obligation: https://bestgrowthstocks.com/soun-analysis/ About SoundHound AI SoundHound AI (Nasdaq: SOUN), a global leader in conversational intelligence, offers voice AI solutions that let businesses offer incredible conversational experiences to their customers. Built on proprietary technology, SoundHound’s voice AI delivers best-in-class speed and accuracy in numerous languages to product creators across automotive, TV, and IoT, and to customer service industries via groundbreaking AI-driven products like Smart Answering, Smart Ordering, and Dynamic Drive Thru, an AI-powered multimodal food ordering solution. Along with SoundHound Chat AI, a powerful voice assistant with integrated Generative AI, SoundHound powers millions of products and services, and processes billions of interactions each year for world class businesses. About Best Growth Stocks Best Growth Stocks is a leading independent equity research and corporate access firm focused on finding and reporting on the best growth stocks utilizing our exclusive ai-assisted research. BGS is also a financial news provider, focused on giving investors direct access to CEOs of promising, publicly-traded companies, and market experts. Our CEO interviews aim to answer the questions that rest on the minds of current and future shareholders. This is not to be construed as financial advice. Please consult with a licensed financial advisor before making any investment decisions. Media Contact Best Growth Stocks Senior Editor: Steve Macalbry Editor@BestGrowthStocks.com SOURCE: BestGrowthStocks.Com Contact Details Media Source LLC Steve Macalbry +1 989-274-7778 Editor@bestgrowthstocks.com

July 22, 2024 07:00 AM Eastern Daylight Time

Image
Article thumbnail News Release

LeadStar Marketplace Unleashes Groundbreaking Enhancements to Its Lead-Generation Platform

AmeriLife

LeadStar Marketplace, the proprietary, private leads platform created exclusively for AmeriLife -affiliated agents, announced today the launch of LeadStar 2.0, which features significant enhancements to its robust platform, designed to revolutionize how licensed insurance agents acquire quality leads for consumers seeking Medicare, Medicare Advantage, Affordable Care Act (ACA), and Final Expense (FE) insurance coverage. LeadStar 2.0 is available immediately to all existing customers. In collaboration with its customer base and affiliated health agencies, the LeadStar team has listened to what sales professionals value in today’s lead generation landscape, resulting in the upgraded LeadStar 2.0 platform. The platform’s enhanced approach to supplying leads features an extended lead catalog, multi-media channel capabilities, and advanced optimization technologies to set a new standard for lead generation efficiency and effectiveness. “At LeadStar, we are dedicated to pushing the boundaries of what's possible in lead generation,” said William DeCourcy, Chief Lead Generation Officer for AmeriLife. “These enhancements are a testament to our ongoing efforts to innovate and improve our services. We believe the new features will empower our clients to succeed even more in their marketing and sales endeavors.” The enhanced LeadStar 2.0 platform is designed to meet the demands of the evolving health and life insurance marketplace, ensuring licensed agents connect with the right prospects more efficiently than before. Extended Lead Catalog The extended lead catalog allows users to diversify and target a more comprehensive network of potential customers across various multimedia platforms and demographics. This expansion means agents can connect with the right prospects at the right time, which should dramatically increase conversion rates. LeadStar 2.0’s expansion targets social media, inbounds, direct mail, and transfers with real-time data across Medicare, MA, ACA, and FE. This deeper level of marketing funnel visibility offers more substantial visibility to each lead by understanding their customer journey before the sales process begins. Expanded Multimedia Channel Supply LeadStar 2.0 integrates a wealth of multi-media channel leads into its platform. Agents can now connect with potential customers through multiple touchpoints, including social media, email, and mobile, all within a unified system tailored to meet specific needs or strategies. This holistic approach streamlines the lead generation process, enhances user engagement and interaction, and aims to provide the lowest CPA possible. More Substantial Lead Delivery Moreover, LeadStar 2.0 introduces enhanced optimization capabilities to its platform. Advanced algorithms and machine learning power the platform and offer more intelligent lead matching and predictive lead scoring. These features ensure clients receive relevant and high-potential leads, reducing the time and effort they will spend on lead qualification and follow-up. For more information about LeadStar and the enhanced lead-generation platform, please email leadstar@leadstarhub.com or request access at LeadStarHub.com. ### About LeadStar LeadStar is an industry-leading enterprise leads program that delivers the compliant, reliable, and performative leads that today’s health and life insurance agents need to grow their books of business and maximize their success. Powered by AmeriLife and exclusively for the company’s affiliated agents, LeadStar’s suite of solutions includes LeadStar Marketplace, LeadStar Connect, and LeadStar Direct. For more information, contact an AmeriLife-affiliated marketing company or visit LeadStarHub.com. About AmeriLife AmeriLife’s strength is its mission: to provide insurance and retirement solutions to help people live longer, healthier lives. In doing so, AmeriLife has become recognized as the leader in developing, marketing, and distributing life and health insurance, annuities, and retirement planning solutions to enhance the lives of pre-retirees and retirees across the United States. For over 50 years, AmeriLife has partnered with top insurance carriers to provide value and quality to customers through a distribution network of over 300,000 insurance agents and advisors and 120 marketing organizations and insurance agency locations nationwide. For more information, visit AmeriLife.com and follow AmeriLife on Facebook and LinkedIn. Contact Details Media Jeff Maldonado Media@amerilife.com Company Website https://amerilife.com/

July 18, 2024 12:00 PM Eastern Daylight Time

Article thumbnail News Release

ABVC BioPharma's CEO Discusses New Drug Development and AI Integration

ABVC BioPharma

After successfully completing Phase II clinical trials for their medication to treat Major Depressive Disorder, ABVC BioPharma Inc. and AiBtl BioPharma Inc. are now embarking on a groundbreaking clinical study focused on Depression in Cancer Patients. This new study will integrate AI-driven solutions to address the significant challenge of depression among cancer patients, a condition that often complicates treatment and adversely affects overall quality of life. Dr. Uttam Patil shared with Steve Darling from Proactive that the study aims to gain a deeper understanding of the prevalence and impact of depression in cancer patients. It will explore innovative therapeutic approaches by integrating real-time patient monitoring and enhanced patient analysis through an AI model. This advanced methodology is expected to increase the lead time for clinical trials, utilizing novel and sophisticated treatment protocols. The clinical study will be conducted at the renowned Cedars-Sinai Medical Center, involving cancer patients who experience depressive symptoms. By leveraging advanced AI technologies and employing cutting-edge diagnostic and therapeutic techniques, the study aims to monitor and treat depression in participants under meticulous medical supervision. Dr. Patil emphasized that the integration of AI-driven solutions in this clinical study represents a significant leap forward in the treatment of depression in cancer patients. The use of real-time patient monitoring and AI-based analysis is anticipated to provide valuable insights and improve patient outcomes, setting a new standard for clinical trials in this area. The collaboration between ABVC BioPharma and AiBtl BioPharma highlights their commitment to advancing healthcare through innovative solutions. This study is poised to make a substantial impact on the management of depression in cancer patients, offering hope for improved quality of life and better treatment outcomes. Through this pioneering study, ABVC BioPharma and AiBtl BioPharma are at the forefront of integrating technology with healthcare, paving the way for future advancements in the field. The companies are dedicated to utilizing AI to enhance patient care and accelerate the development of effective treatments for depression in cancer patients. Contact Details Proactive North America +1 604-688-8158 na-editorial@proactiveinvestors.com

July 18, 2024 10:31 AM Eastern Daylight Time

Video
Article thumbnail News Release

Forum Health Breaks into Denver Market with Acquisition of Concierge Functional and Regenerative Medicine Practice

Forum Health

Forum Health, LLC, a nationwide network of integrative and functional medicine providers and a pioneer in personalized healthcare, is expanding into a leading wellness-focused city with its acquisition of RevolutionaryMD in Denver, CO. Learn more about RevolutionaryMD. Renowned for its proclivity for health and wellness and prestigious medical research institutions, Denver is the ideal setting for a clinic rooted in personalized, cutting-edge healthcare. Phil Hagerman, Forum Health CEO: “Dr. Grover’s development of his revolutionary functional, regenerative, and anti-aging medical center aligns perfectly with the Forum Health clinic model, making this expansion a natural fit. His thirty years of success and expertise in central Denver is invaluable as we expand to a new state, enhancing the practice’s availability and offerings for wellness-focused patients.” The founder of RevolutionaryMD center in Cherry Creek North, Fred Grover, Jr., MD, is a Board-Certified Family Physician with training and certifications in Integrative, Functional, and Anti-Aging Medicine. He brings a wealth of experience and expertise to Forum Health's expanding network. Fred Grover Jr., MD, RevolutionaryMD Founder: “I’m excited to join Forum Health and grow our services and availability to help patients find a proactive approach to healthcare. We embrace the future of medicine by offering a robust preventative care model to treat the root cause of chronic conditions.” In addition to traditional testing, RevolutionaryMD offers genomic panels, advanced cardiovascular and cancer screening, inflammatory, and nutritional testing. It also employs AI for precise, personalized recommendations, moving beyond the depersonalized, often suboptimal outcomes of standard allopathic medicine. RevolutionaryMD has pioneered the concierge approach of functional medicine, advancing personalized healthcare with the latest treatments in: Anti-Aging and Regenerative Medicine for Improved Healthspan and Lifespan Bioidentical Hormone Replacement Therapy and Restoration Sexual Health and Wellness Aesthetic Dermatology Mind and Body Balancing Through Brain Health Modalities Integrated Ketamine and Sound Therapy for Depression IV Therapy for Post-COVID Syndrome, Inflammation and Healthy Mitochondrial Function Dr. Grover's dedication to functional and integrative medicine is evident in his role as an assistant clinical professor at the University of Colorado, Denver, his Board Certifications in Anti-Aging and Integrative Holistic Medicine, and his authorship of "Spiritual Genomics" and "Awakening Gaia." About Forum Health, LLC Forum Health, LLC is a nationwide provider of personalized healthcare steeped in the powerful principles of functional and integrative medicine. Our providers take a root-cause approach to care exploring lifestyle, environment, and genetics to help each patient achieve their ultimate health goals. Members have access to advanced medical treatments and technology, with care plans informed by data analytics and collaborative relationships. For more, visit www.forumhealth.com. Contact Details Britt Wittelsberger +1 410-852-0738 bwittelsberger@forumhealth.com Company Website https://forumhealth.com

July 18, 2024 08:50 AM Eastern Daylight Time

Image
Article thumbnail News Release

Ascend Wellness CEO Outlines Company's Growth Strategy and Market Expansion Plans

Ascend Wellness Holdings

Ascend Wellness CEO John Hartman joined Steve Darling from Proactive to discuss the company’s current status and future plans. Ascend Wellness, a prominent multi-state cannabis operator in the United States, has established its presence primarily in the Midwest, Northeast, and Mid-Atlantic regions. The company, now in its fifth year of operation, has expanded its footprint to seven states, including Ohio and Pennsylvania, both of which are transitioning to recreational cannabis use. During the interview, Hartman emphasized Ascend Wellness's strategic approach of focusing on select markets and maximizing the number of dispensaries allowed in each state. This targeted strategy is aimed at optimizing market penetration and ensuring robust growth. Drawing on his extensive background in wholesale, retail, and manufacturing, Hartman highlighted the company's emphasis on effective capital deployment and growth through mergers and acquisitions (M&A). A significant development discussed was the refinancing of a term loan due in August 2025. This financial maneuver provides Ascend Wellness with a five-year runway to concentrate on growth initiatives. The refinancing is expected to enhance the company's balance sheet management, providing greater financial stability and flexibility. Contact Details Proactive North America +1 604-688-8158 na-editorial@proactiveinvestors.com

July 17, 2024 10:42 AM Eastern Daylight Time

Video
12345 ... 277